BioCentury | Oct 15, 2015
Distillery Therapeutics

Therapeutics: p53

Cancer INDICATION: Lymphoma Mouse studies suggest inhibiting p53 could help prevent radiotherapy-induced thymic lymphoma and acute hematologic toxicity. In normal mice receiving whole-body irradiation, p53 knockdown decreased acute apoptosis of thymic and bone marrow cells,...
BioCentury | Sep 30, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Tumor protein p53 (TP53; p53) Cell culture studies identified short oligonucleotide inhibitors of p53 synthesis that could help prevent chemotherapy-induced damage to healthy cells....
BioCentury | Sep 7, 2009

On deck in AML

On deck in AML Company Product Description Status in AML Genzyme Corp. (NASDAQ:GENZ) Clolar clofarabine Second-generation purine nucleoside analog Under FDA review (A) Vion Pharmaceuticals Inc. (OTCBB:VION) Onrigin laromustine Sulfonyl hydrazine DNA alkylating agent Under...
BioCentury | Aug 27, 2009
Targets & Mechanisms

Melanoma: eaten up inside

Autophagy's dual pro- and antiapoptotic roles make it hard to determine whether inducing the process could be a viable strategy to treat cancer. In melanoma, a team led by Spanish researchers thinks the answer is...
BioCentury | Oct 20, 2008
Clinical News

Aezea cenersen sodium regulatory update

EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for Aezea cenersen to treat chronic lymphocytic leukemia (CLL). The antisense oligonucleotide against p53 is in Phase II testing...
BioCentury | Jan 15, 2007
Company News

AVI BioPharma, Eleos deal

The companies signed a cross-license agreement to develop antisense compounds targeting p53. Eleos gets an exclusive license to AVII's Neugene antisense chemistry to develop compounds targeting p53 to treat cancer, and AVII gets an exclusive...
BioCentury | May 10, 2004

Midwest work ethic

Midwest work ethic Company Location Round Proposed amt ($M) Focus Notes APT St. Louis, Mo. B $8.0 Stroke Hopes the proceeds will provide about two years of runway and allow it to submit INDs for...
Items per page:
1 - 7 of 7